Tirzepatide is a prescription medication made by Eli Lilly that is sold under the brand names Mounjaro (approved for type 2 diabetes in 2022) and Zepbound (approved for obesity in 2023). It belongs to a newer class of drugs that work by mimicking gut hormones to regulate blood sugar, appetite, and metabolism. What makes tirzepatide stand out from other medications in its class is that it activates two hormone receptors at once: the GLP-1 receptor and the GIP receptor. Most similar drugs, such as semaglutide (Ozempic, Wegovy), only activate the GLP-1 receptor. As clinicians and researchers began tracking patients taking tirzepatide for weight loss, they noticed something unexpected: many people reported drinking less alcohol, experiencing fewer cravings for addictive substances, and feeling less drawn to compulsive behaviors. These observations prompted formal scientific investigation into whether tirzepatide could play a role in addiction medicine.
To understand why tirzepatide might help with addiction, it helps to know a little about how the brain processes reward. When someone uses alcohol, opioids, or other addictive substances, those substances flood the brain’s reward system with dopamine, the chemical associated with pleasure and motivation. Over time, the brain recalibrates around that flood of dopamine, making it harder to feel good without the substance and generating powerful cravings to use again. GLP-1 receptor activation has already been shown to dampen reward signaling and reduce dopamine release in key brain regions like the nucleus accumbens, which is sometimes called the brain’s reward center. Tirzepatide does this too, but it also activates GIP receptors, which are found throughout the brain and appear to enhance synaptic plasticity, meaning the brain’s ability to rewire itself. Early research suggests that activating both receptors together may produce more durable changes in the reward circuit than activating GLP-1 alone. Scientists have also observed that tirzepatide appears to cause lasting changes in the lateral septum, a brain region involved in regulating emotion and motivation, with evidence of epigenetic changes that could make its effects longer-lasting than previously seen with single-receptor drugs.
What Has Research Found About Tirzepatide And Substance Cravings?
Preclinical studies published in eBioMedicine and The Lancet family of journals in 2026 found that tirzepatide significantly reduced voluntary alcohol consumption in both male and female rats. The drug worked in a dose-dependent way, meaning higher doses produced stronger reductions in drinking. Importantly, tirzepatide also prevented relapse-like drinking behavior and reduced the spike in dopamine that alcohol normally triggers in the nucleus accumbens. Crucially, these effects did not weaken with repeated use, a promising sign that the body does not quickly build tolerance to them. A separate 2026 study found that tirzepatide reduced cocaine self-administration and cocaine-seeking behavior in rodents, with two independent laboratories confirming the results. A large real-world analysis of over 606,000 veterans published in the BMJ in 2026 found that people taking GLP-1 class medications, which included tirzepatide users, had 40 percent fewer overdoses and 50 percent fewer drug-related deaths than comparable patients not on these medications.
Human clinical trials are now underway. The TAB Trial (NCT06651177), funded by the NIH HEAL Initiative with $7.45 million, is testing tirzepatide as an addition to buprenorphine treatment for opioid use disorder in a multi-site, double-blind, placebo-controlled study led by researchers at the University of Cincinnati. Four additional registered clinical trials are studying tirzepatide specifically for alcohol use disorder, including the STREAM trial (NCT06727331) and the DUALPSYCHIATRY trial (NCT06939088). A social media survey of 153 tirzepatide users conducted by Virginia Tech researchers and published in Scientific Reports in 2023 also found that participants reported significantly lower alcohol intake and lower scores on a validated alcohol use screening tool compared to before starting the medication.
How Does Tirzepatide Differ From Other Medications Being Studied For Addiction?
Semaglutide (Ozempic, Wegovy) is currently the most widely studied GLP-1 drug in addiction research, and early data suggest it can reduce alcohol and drug cravings in some people. Tirzepatide builds on that potential because it activates an additional receptor, the GIP receptor, that semaglutide does not. The GIP receptor is expressed in areas of the brain involved in learning, memory, and reward, and activating it may help the brain form new, healthier patterns while simultaneously reducing the pull of addictive substances. This dual action could be especially meaningful for people whose addiction is intertwined with emotional pain, anxiety, or depression, because GIP signaling may support emotional regulation alongside craving reduction. Researchers have also noted that tirzepatide appears to produce more sustained changes in the brain than single-receptor drugs in animal models, which raises the possibility that patients might maintain benefits for longer periods. While tirzepatide is not currently approved to treat any addiction, it is being studied as a complement to existing treatments like buprenorphine, not as a replacement for them, which fits well with the comprehensive, individualized approach to recovery that modern treatment programs emphasize.
What is tirzepatide and what is it approved for?
Tirzepatide is a prescription drug made by Eli Lilly. It is FDA-approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for obesity (2023). It works by activating both GLP-1 and GIP hormone receptors, which sets it apart from similar medications that only target GLP-1. It is not currently approved to treat addiction or substance use disorders.
Is tirzepatide being tested as an addiction treatment?
Yes. Multiple clinical trials are underway. The NIH-funded TAB Trial is testing tirzepatide alongside buprenorphine for opioid use disorder, and four separate trials are studying it for alcohol use disorder. Animal studies have shown it reduces alcohol and cocaine use as well as related dopamine spikes. A large veterans study also found GLP-1 drug users had far fewer overdoses and drug-related deaths.
How might tirzepatide help someone in recovery?
Researchers believe tirzepatide quiets the brain’s reward signals that drive cravings. By activating both GLP-1 and GIP receptors, it may reduce dopamine surges triggered by substances and help the brain rewire itself over time. Some animal studies found these changes were durable without tolerance developing. In humans, many patients have reported drinking less while taking it. Clinical trials are working to confirm these effects.
